Apogee Therapeutics, Inc. APGE
Updated: 11 Sep 2026
No signal published yet
We already track Apogee Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Apogee Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Apogee Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On September 3, 2026, AbbVie completed its acquisition of Apogee Therapeutics for $135.11 per share in cash, valuing the company at an equity value of approximately $10.9 billion. Following the transaction, Apogee's common stock ceased trading and was delisted from Nasdaq.
What Firelda Watch includes for Apogee Therapeutics, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Apogee Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Apogee Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more